Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INCCOLL · Entity 5169 | Director | May 14, 2026 | May 18, 2026 |
| IMMUNE DESIGN CORP.IMDZ · Entity 158527 | Director · President and CEO | April 02, 2019 | April 04, 2019 |
| STANDARD BIOTOOLS INC.LAB · Entity 6116 | Director | June 14, 2023 | June 17, 2023 |
| Vaxcyte, Inc.PCVX · Entity 1164 | Director | June 15, 2026 | June 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
COLLEGIUM PHARMACEUTICAL, INC
Report date May 14, 2026 · Filed May 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 28,323 |
Reported balance
After 2026-05-14 transaction · row 1
1 source rowRow 1 · 2026-05-14 · Grant · Acquired 8,741 · Balance 28,323 F1: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on the earlier of May 14, 2027, or the date of the Issuer's 2027 Annual Meeting of Shareholders, subject to the director's continued service with the Issuer. The RSUs will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the Issuer, in shares of the Issuer's common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on the earlier of May 14, 2027, or the date of the Issuer's 2027 Annual Meeting of Shareholders, subject to the director's continued service with the Issuer. The RSUs will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the Issuer, in shares of the Issuer's common stock.
IMMUNE DESIGN CORP.
Report date April 02, 2019 · Filed April 04, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-04-02 transaction · row 1
1 source rowRow 1 · 2019-04-02 · Disposition to issuer · Disposed 35,576 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated February 20, 2019, by and among the Immune Design Corp. (the "Issuer"), Merck Sharp & Dohme Corp., a New Jersey corporation ("Parent") and Cascade Merger Sub Inc., a Delaware corporation ("Purchaser"), on April 2, 2019, Purchaser merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, the Issuer's common stock were cancelled and converted into the right to receive $5.85 in cash per share, less any required withholding, subject to the terms and conditions of the Merger Agreement ("Merger Consideration"). |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2019-04-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-04-02 · Disposition to issuer · Disposed 121,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these unvested restricted stock units vested automatically in accordance with their terms and were cancelled and automatically converted into the right to receive the Merger Consideration in respect of each share of Issuer common stock underlying such awards. F3: Not Applicable. |
| Stock Option (Rt to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.31 | Direct | 0 |
Reported balance
After 2019-04-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-04-02 · Disposition to issuer · Disposed 195,289 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) the Merger Consideration over (y) the exercise price payable per share. F3: Not Applicable. |
| Stock Option (Rt to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.31 | Direct | 0 |
Reported balance
After 2019-04-02 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-04-02 · Disposition to issuer · Disposed 67,277 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) the Merger Consideration over (y) the exercise price payable per share. F3: Not Applicable. |
| Stock Option (Rt to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.48 | Direct | 0 |
Reported balance
After 2019-04-02 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-04-02 · Disposition to issuer · Disposed 61,161 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) the Merger Consideration over (y) the exercise price payable per share. F3: Not Applicable. |
| Stock Option (Rt to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.23 | Direct | 0 |
Reported balance
After 2019-04-02 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-04-02 · Disposition to issuer · Disposed 244,648 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) the Merger Consideration over (y) the exercise price payable per share. F3: Not Applicable. |
| Stock Option (Rt to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.60 | Direct | 0 |
Reported balance
After 2019-04-02 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-04-02 · Disposition to issuer · Disposed 175,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) the Merger Consideration over (y) the exercise price payable per share. F3: Not Applicable. |
| Stock Option (Rt to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.05 | Direct | 0 |
Reported balance
After 2019-04-02 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2019-04-02 · Disposition to issuer · Disposed 216,500 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) the Merger Consideration over (y) the exercise price payable per share. F3: Not Applicable. |
| Stock Option (Rt to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.40 | Direct | 0 |
Reported balance
After 2019-04-02 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2019-04-02 · Disposition to issuer · Disposed 263,009 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) the Merger Consideration over (y) the exercise price payable per share. F3: Not Applicable. |
| Stock Option (Rt to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.31 | Direct | 0 |
Reported balance
After 2019-04-02 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2019-04-02 · Disposition to issuer · Disposed 293,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) the Merger Consideration over (y) the exercise price payable per share. F3: Not Applicable. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated February 20, 2019, by and among the Immune Design Corp. (the "Issuer"), Merck Sharp & Dohme Corp., a New Jersey corporation ("Parent") and Cascade Merger Sub Inc., a Delaware corporation ("Purchaser"), on April 2, 2019, Purchaser merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, the Issuer's common stock were cancelled and converted into the right to receive $5.85 in cash per share, less any required withholding, subject to the terms and conditions of the Merger Agreement ("Merger Consideration").
F2: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these unvested restricted stock units vested automatically in accordance with their terms and were cancelled and automatically converted into the right to receive the Merger Consideration in respect of each share of Issuer common stock underlying such awards.
F3: Not Applicable.
F4: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) the Merger Consideration over (y) the exercise price payable per share.
STANDARD BIOTOOLS INC.
Report date June 14, 2023 · Filed June 17, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 126,844 |
Reported balance
After 2023-06-14 transaction · row 1
1 source rowRow 1 · 2023-06-14 · Grant · Acquired 26,376 · Balance 126,844 F1: Consists of Restricted Stock Units. Each Restricted Stock Unit represents the right to receive one share of common stock upon vesting. The Restricted Stock Units vest in full on the earlier to occur of June 14, 2024 and one day prior to the date of the Company's next annual meeting of stockholders subject to the Reporting Person's continued service through the applicable vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.18 · Expires 2033-06-14 | Direct | 35,380 |
Reported balance
After 2023-06-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-06-14 · Grant · Acquired 35,380 · Balance 35,380 F2: The Option becomes exercisable in twelve equal monthly increments beginning on July 14, 2023 subject to the Reporting Person's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of Restricted Stock Units. Each Restricted Stock Unit represents the right to receive one share of common stock upon vesting. The Restricted Stock Units vest in full on the earlier to occur of June 14, 2024 and one day prior to the date of the Company's next annual meeting of stockholders subject to the Reporting Person's continued service through the applicable vesting date.
F2: The Option becomes exercisable in twelve equal monthly increments beginning on July 14, 2023 subject to the Reporting Person's continued service through the applicable vesting date.
Vaxcyte, Inc.
Report date June 15, 2026 · Filed June 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,856 |
Reported balance
After 2026-06-15 transaction · row 1
1 source rowRow 1 · 2026-06-15 · Grant · Acquired 2,265 · Balance 6,856 F1: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Pursuant to the Issuer's Nonqualified RSU Deferral Program for Non-Employee Directors, the Reporting Person has deferred delivery of all of such vested RSUs to the earlier of (i) a separation from service, or (ii) a qualifying change in control. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $49.56 · Expires 2036-06-15 | Direct | 11,389 |
Reported balance
After 2026-06-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-15 · Grant · Acquired 11,389 · Balance 11,389 F2: The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. |
| Common StockSEC Table I · non-derivative | IndirectBy Family Trust | 5,625 |
Reported balance
Holding disclosure · report date 2026-06-15 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 5,625 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Pursuant to the Issuer's Nonqualified RSU Deferral Program for Non-Employee Directors, the Reporting Person has deferred delivery of all of such vested RSUs to the earlier of (i) a separation from service, or (ii) a qualifying change in control.
F2: The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Keenova Therapeutics plc
Report date June 16, 2022 · Filed June 21, 2022
Section 16 reporting ended · disclosed 2022-06-21. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 02, 2019 Filed Apr 4, 2019 17:14 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | Disposition to issuerRestricted Stock Units · Derivative | 121,000 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001209191-19-023685 · doc4.xml · derivative · entry 2 Paya Carlos V · CIK 0001606244 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 121,000 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these unvested restricted stock units vested automatically in accordance with their terms and were cancelled and automatically converted into the right to receive the Merger Consideration in respect of each share of Issuer common stock underlying such awards. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these unvested restricted stock units vested automatically in accordance with their terms and were cancelled and automatically converted into the right to receive the Merger Consideration in respect of each share of Issuer common stock underlying such awards. F3 · derivative.expiration_date: Not Applicable. Read SEC document |
| April 02, 2019 Filed Apr 4, 2019 17:14 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | Disposition to issuerCommon Stock | 35,576 | $5.85 | $208,119.60 |
DisclosureSEC source: 0001209191-19-023685 · doc4.xml · nonDerivative · entry 1 Paya Carlos V · CIK 0001606244 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated February 20, 2019, by and among the Immune Design Corp. (the "Issuer"), Merck Sharp & Dohme Corp., a New Jersey corporation ("Parent") and Cascade Merger Sub Inc., a Delaware corporation ("Purchaser"), on April 2, 2019, Purchaser merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, the Issuer's common stock were cancelled and converted into the right to receive $5.85 in cash per share, less any required withholding, subject to the terms and conditions of the Merger Agreement ("Merger Consideration"). Read SEC document |
| March 23, 2019 Filed Mar 26, 2019 21:49 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | Exercise / conversionRestricted Stock Units · Derivative | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001162194-19-000023 · wf-form4_155363693881535.xml · derivative · entry 2 Paya Carlos V · CIK 0001606244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 2,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of FLDM common stock upon vesting of the unit. F2 · derivative.exercise_date: On March 23, 2017, the Reporting Person was granted 10,000 Restricted Stock Units of which 25% of the total number of shares underlying the Restricted Stock Units have vested and will continue to vest each anniversary after the date of grant on the same day of the month as the date of grant, subject to continued service as a director. F2 · derivative.expiration_date: On March 23, 2017, the Reporting Person was granted 10,000 Restricted Stock Units of which 25% of the total number of shares underlying the Restricted Stock Units have vested and will continue to vest each anniversary after the date of grant on the same day of the month as the date of grant, subject to continued service as a director. Read SEC document |
| March 23, 2019 Filed Mar 26, 2019 21:49 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | Exercise / conversionCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001162194-19-000023 · wf-form4_155363693881535.xml · nonDerivative · entry 1 Paya Carlos V · CIK 0001606244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,856 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2019 Filed Feb 15, 2019 02:00 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | GrantCommon Stock | 4,522 | $0.00 | $0.00 |
DisclosureSEC source: 0001162194-19-000006 · wf-form4_155019600857226.xml · nonDerivative · entry 1 Paya Carlos V · CIK 0001606244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,356 F1 · shares: Each Restricted Stock Unit represents the contingent right to receive one share of FLDM common stock upon vesting of the unit. Subject to the Reporting Person's continued service with the Issuer through each applicable vesting date, twenty-five percent (25%) of the shares underlying the Restricted Stock Units shall vest quarterly on the last day of each quarter during 2019. Read SEC document |
| January 07, 2019 Filed Jan 7, 2019 20:36 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | SaleCommon Stock | 13,014 | $1.58 | $20,590.75 |
DisclosureSEC source: 0001209191-19-002671 · doc4.xml · nonDerivative · entry 2 Paya Carlos V · CIK 0001606244 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,576 F3 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan that was included in the Reporting Person's restricted stock unit agreements, dated January 4, 2016, January 4, 2017 and January 4, 2018, in order to satisfy a tax liability incurred upon the vesting of restricted stock units on January 4, 2019. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.55 to $1.63 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 03, 2019 Filed Jan 7, 2019 20:36 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | GrantStock Option (right to buy) · Derivative | 293,000 | $0.00 Strike: $1.31 | $0.00 |
DisclosureSEC source: 0001209191-19-002671 · doc4.xml · derivative · entry 3 Paya Carlos V · CIK 0001606244 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 293,000 Underlying: Common Stock · 293,000 shares Expires 2029-01-03 F5 · derivative.exercise_date: One quarter of the shares underlying the option will vest on January 3, 2020, and the remainder of the shares underlying the option will vest at a rate of 1/24th per month thereafter, subject to the Reporting Person's continuous service through each such date. Read SEC document |
| January 03, 2019 Filed Jan 7, 2019 20:36 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | GrantCommon Stock | 63,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-002671 · doc4.xml · nonDerivative · entry 1 Paya Carlos V · CIK 0001606244 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,590 F1 · security: Each restricted stock unit represents a contingent right to receive one share of Immune Design Corp. common stock. F2 · shares: Restricted stock unit shall vest in a series of three equal consecutive annual installments beginning on January 4, 2020, subject to the Reporting Person's continuous service through each such date. Read SEC document |
| July 17, 2018 Filed Jul 19, 2018 18:05 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | GrantStock Option (Rt to Buy) · Derivative | 96,874 | Not disclosed Strike: $4.40 | Not disclosed |
DisclosureSEC source: 0001209191-18-043396 · doc4.xml · derivative · entry 14 Paya Carlos V · CIK 0001606244 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,874 Underlying: Common Stock · 96,874 shares Expires 2025-07-17 F12 · price: On July 17, 2018, the issuer canceled, pursuant to the issuer's option exchange program, an option for 169,529 shares of the issuer's common stock granted to the reporting person on January 4, 2016. In exchange, the reporting person received a replacement option, for 96,874 shares, having an exercise price of $4.40 per share. F3 · derivative.exercise_date: The option vests in twenty four (24) equal consecutive monthly installments beginning on August 17, 2018. Read SEC document |
| July 17, 2018 Filed Jul 19, 2018 18:05 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | Disposition to issuerStock Option (Rt to Buy) · Derivative | 169,529 | Not disclosed Strike: $19.39 | Not disclosed |
DisclosureSEC source: 0001209191-18-043396 · doc4.xml · derivative · entry 13 Paya Carlos V · CIK 0001606244 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 169,529 shares Expires 2026-01-04 F12 · price: On July 17, 2018, the issuer canceled, pursuant to the issuer's option exchange program, an option for 169,529 shares of the issuer's common stock granted to the reporting person on January 4, 2016. In exchange, the reporting person received a replacement option, for 96,874 shares, having an exercise price of $4.40 per share. F10 · derivative.exercise_date: The option provided for vesting of 1/4th of the shares underlying the option on January 4, 2017 and the remainder of the shares underlying the option at a rate of 1/36th per month thereafter. Read SEC document |
| July 17, 2018 Filed Jul 19, 2018 18:05 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | GrantStock Option (Rt to Buy) · Derivative | 3,127 | Not disclosed Strike: $4.40 | Not disclosed |
DisclosureSEC source: 0001209191-18-043396 · doc4.xml · derivative · entry 12 Paya Carlos V · CIK 0001606244 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,127 Underlying: Common Stock · 3,127 shares Expires 2025-07-17 F11 · price: On July 17, 2018, the issuer canceled, pursuant to the issuer's option exchange program, an option for 5,471 shares of the issuer's common stock granted to the reporting person on January 4, 2016. In exchange, the reporting person received a replacement option, for 3,127 shares, having an exercise price of $4.40 per share. F3 · derivative.exercise_date: The option vests in twenty four (24) equal consecutive monthly installments beginning on August 17, 2018. Read SEC document |
| July 17, 2018 Filed Jul 19, 2018 18:05 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | Disposition to issuerStock Option (Rt to Buy) · Derivative | 5,471 | Not disclosed Strike: $19.39 | Not disclosed |
DisclosureSEC source: 0001209191-18-043396 · doc4.xml · derivative · entry 11 Paya Carlos V · CIK 0001606244 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,471 shares Expires 2026-01-04 F11 · price: On July 17, 2018, the issuer canceled, pursuant to the issuer's option exchange program, an option for 5,471 shares of the issuer's common stock granted to the reporting person on January 4, 2016. In exchange, the reporting person received a replacement option, for 3,127 shares, having an exercise price of $4.40 per share. F10 · derivative.exercise_date: The option provided for vesting of 1/4th of the shares underlying the option on January 4, 2017 and the remainder of the shares underlying the option at a rate of 1/36th per month thereafter. Read SEC document |
| July 17, 2018 Filed Jul 19, 2018 18:05 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | GrantStock Option (rt to Buy) · Derivative | 60,000 | Not disclosed Strike: $4.40 | Not disclosed |
DisclosureSEC source: 0001209191-18-043396 · doc4.xml · derivative · entry 10 Paya Carlos V · CIK 0001606244 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2025-07-17 F9 · price: On July 17, 2018, the issuer canceled, pursuant to the issuer's option exchange program, an option for 90,000 shares of the issuer's common stock granted to the reporting person on January 7, 2015. In exchange, the reporting person received a replacement option, for 60,000 shares, having an exercise price of $4.40 per share. F3 · derivative.exercise_date: The option vests in twenty four (24) equal consecutive monthly installments beginning on August 17, 2018. Read SEC document |
| July 17, 2018 Filed Jul 19, 2018 18:05 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | Disposition to issuerStock Option (Rt to Buy) · Derivative | 90,000 | Not disclosed Strike: $13.00 | Not disclosed |
DisclosureSEC source: 0001209191-18-043396 · doc4.xml · derivative · entry 9 Paya Carlos V · CIK 0001606244 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 90,000 shares Expires 2025-10-30 F9 · price: On July 17, 2018, the issuer canceled, pursuant to the issuer's option exchange program, an option for 90,000 shares of the issuer's common stock granted to the reporting person on January 7, 2015. In exchange, the reporting person received a replacement option, for 60,000 shares, having an exercise price of $4.40 per share. F8 · derivative.exercise_date: The option provided for vesting of 37.5% of the option on each of October 30, 2016 and 2017 with the remainder of the shares underlying the option on October 30, 2018. Read SEC document |
| July 17, 2018 Filed Jul 19, 2018 18:05 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | GrantStock Option (Rt to Buy) · Derivative | 48,775 | Not disclosed Strike: $4.40 | Not disclosed |
DisclosureSEC source: 0001209191-18-043396 · doc4.xml · derivative · entry 8 Paya Carlos V · CIK 0001606244 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,775 Underlying: Common Stock · 48,775 shares Expires 2025-07-17 F7 · price: On July 17, 2018, the issuer canceled, pursuant to the issuer's option exchange program, an option for 97,550 shares of the issuer's common stock granted to the reporting person on January 7, 2015. In exchange, the reporting person received a replacement option, for 48,775 shares, having an exercise price of $4.40 per share. F3 · derivative.exercise_date: The option vests in twenty four (24) equal consecutive monthly installments beginning on August 17, 2018. Read SEC document |
| July 17, 2018 Filed Jul 19, 2018 18:05 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | Disposition to issuerStock Option (Rt to Buy) · Derivative | 97,550 | Not disclosed Strike: $31.00 | Not disclosed |
DisclosureSEC source: 0001209191-18-043396 · doc4.xml · derivative · entry 7 Paya Carlos V · CIK 0001606244 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 97,550 shares Expires 2025-01-07 F7 · price: On July 17, 2018, the issuer canceled, pursuant to the issuer's option exchange program, an option for 97,550 shares of the issuer's common stock granted to the reporting person on January 7, 2015. In exchange, the reporting person received a replacement option, for 48,775 shares, having an exercise price of $4.40 per share. F5 · derivative.exercise_date: The option provided for 1/4th of the shares underlying the option on January 1, 2016 and the remainder of the shares at a rate of 1/36th per month thereafter. Read SEC document |
| July 17, 2018 Filed Jul 19, 2018 18:05 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | GrantStock Option (Rt to Buy) · Derivative | 1,225 | Not disclosed Strike: $4.40 | Not disclosed |
DisclosureSEC source: 0001209191-18-043396 · doc4.xml · derivative · entry 6 Paya Carlos V · CIK 0001606244 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,225 Underlying: Common Stock · 1,225 shares Expires 2025-07-17 F6 · price: On July 17, 2018, the issuer canceled, pursuant to the issuer's option exchange program, an option for 2,450 shares of the issuer's common stock granted to the reporting person on January 7, 2015. In exchange, the reporting person received a replacement option, for 1,225 shares, having an exercise price of $4.40 per share. F3 · derivative.exercise_date: The option vests in twenty four (24) equal consecutive monthly installments beginning on August 17, 2018. Read SEC document |
| July 17, 2018 Filed Jul 19, 2018 18:05 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | Disposition to issuerStock Option (Rt to Buy) · Derivative | 2,450 | Not disclosed Strike: $31.00 | Not disclosed |
DisclosureSEC source: 0001209191-18-043396 · doc4.xml · derivative · entry 5 Paya Carlos V · CIK 0001606244 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,450 shares Expires 2025-01-07 F6 · price: On July 17, 2018, the issuer canceled, pursuant to the issuer's option exchange program, an option for 2,450 shares of the issuer's common stock granted to the reporting person on January 7, 2015. In exchange, the reporting person received a replacement option, for 1,225 shares, having an exercise price of $4.40 per share. F5 · derivative.exercise_date: The option provided for 1/4th of the shares underlying the option on January 1, 2016 and the remainder of the shares at a rate of 1/36th per month thereafter. Read SEC document |
| July 17, 2018 Filed Jul 19, 2018 18:05 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | GrantStock Option (Rt to Buy) · Derivative | 44,512 | Not disclosed Strike: $4.40 | Not disclosed |
DisclosureSEC source: 0001209191-18-043396 · doc4.xml · derivative · entry 4 Paya Carlos V · CIK 0001606244 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,512 Underlying: Common Stock · 44,512 shares Expires 2025-07-17 F4 · price: On July 17, 2018, the issuer canceled, pursuant to the issuer's option exchange program, an option for 66,767 shares of the issuer's common stock granted to the reporting person on June 23, 2014. In exchange, the reporting person received a replacement option, for 44,512 shares, having an exercise price of $4.40 per share. F3 · derivative.exercise_date: The option vests in twenty four (24) equal consecutive monthly installments beginning on August 17, 2018. Read SEC document |
| July 17, 2018 Filed Jul 19, 2018 18:05 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | Disposition to issuerStock Option (Rt to Buy) · Derivative | 66,767 | Not disclosed Strike: $8.92 | Not disclosed |
DisclosureSEC source: 0001209191-18-043396 · doc4.xml · derivative · entry 3 Paya Carlos V · CIK 0001606244 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 66,767 shares Expires 2024-06-23 F4 · price: On July 17, 2018, the issuer canceled, pursuant to the issuer's option exchange program, an option for 66,767 shares of the issuer's common stock granted to the reporting person on June 23, 2014. In exchange, the reporting person received a replacement option, for 44,512 shares, having an exercise price of $4.40 per share. F1 · derivative.exercise_date: The option provided for vesting of 1/4th of the shares underlying the option on June 23, 2015 and the remainder of the shares at a rate of 1/36th per month thereafter. Read SEC document |
| July 17, 2018 Filed Jul 19, 2018 18:05 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | GrantStock Option (Rt to Buy) · Derivative | 8,496 | Not disclosed Strike: $4.40 | Not disclosed |
DisclosureSEC source: 0001209191-18-043396 · doc4.xml · derivative · entry 2 Paya Carlos V · CIK 0001606244 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,496 Underlying: Common Stock · 8,496 shares Expires 2025-07-17 F2 · price: On July 17, 2018, the issuer canceled, pursuant to the issuer's option exchange program, an option for 12,743 shares of the issuer's common stock granted to the reporting person on June 23, 2014. In exchange, the reporting person received a replacement option, for 8,496 shares, having an exercise price of $4.40 per share. F3 · derivative.exercise_date: The option vests in twenty four (24) equal consecutive monthly installments beginning on August 17, 2018. Read SEC document |
| July 17, 2018 Filed Jul 19, 2018 18:05 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | Disposition to issuerStock Option (Rt to Buy) · Derivative | 12,743 | Not disclosed Strike: $8.92 | Not disclosed |
DisclosureSEC source: 0001209191-18-043396 · doc4.xml · derivative · entry 1 Paya Carlos V · CIK 0001606244 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,743 shares Expires 2024-06-23 F2 · price: On July 17, 2018, the issuer canceled, pursuant to the issuer's option exchange program, an option for 12,743 shares of the issuer's common stock granted to the reporting person on June 23, 2014. In exchange, the reporting person received a replacement option, for 8,496 shares, having an exercise price of $4.40 per share. F1 · derivative.exercise_date: The option provided for vesting of 1/4th of the shares underlying the option on June 23, 2015 and the remainder of the shares at a rate of 1/36th per month thereafter. Read SEC document |
| May 31, 2018 Filed Jun 2, 2018 00:54 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | GrantStock Option (Right to Buy) · Derivative | 10,600 | $0.00 Strike: $5.57 | $0.00 |
DisclosureSEC source: 0001162194-18-000074 · wf-form4_152790080790416.xml · derivative · entry 6 Paya Carlos V · CIK 0001606244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,600 Underlying: Common Stock · 10,600 shares Expires 2028-05-31 F5 · derivative.exercise_date: 1/12th of the shares subject to the Option will vest monthly, subject to continued service as a director, such that the Option will be fully vested on May 31, 2019. Read SEC document |
| May 31, 2018 Filed Jun 2, 2018 00:54 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | GrantCommon Stock | 6,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001162194-18-000074 · wf-form4_152790080790416.xml · nonDerivative · entry 3 Paya Carlos V · CIK 0001606244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,834 F1 · security: Each Restricted Stock Unit represents the contingent right to receive one share of FLDM common stock upon vesting of the unit. F2 · shares: All shares underlying the Restricted Stock Units will fully vest on the earlier to occur of (i) one day prior to the date of the next annual meeting of the stockholders of the Company or (ii) May 31, 2019, in each case subject to recipient's continued service as a director through the applicable vest date. Read SEC document |
| May 30, 2018 Filed Jun 2, 2018 00:54 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | Exercise / conversionRestricted Stock Units · Derivative | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001162194-18-000074 · wf-form4_152790080790416.xml · derivative · entry 5 Paya Carlos V · CIK 0001606244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of FLDM common stock upon vesting of the unit. F4 · derivative.exercise_date: On September 13, 2017, the Reporting Person was granted Restricted Stock Units, vesting fully on the earlier to occur of: (i) one day prior to the date of the next annual meeting of the stockholders of the Company; or (ii) August 1, 2018, subject to continued service as a director through the vesting date. F4 · derivative.expiration_date: On September 13, 2017, the Reporting Person was granted Restricted Stock Units, vesting fully on the earlier to occur of: (i) one day prior to the date of the next annual meeting of the stockholders of the Company; or (ii) August 1, 2018, subject to continued service as a director through the vesting date. Read SEC document |
| May 30, 2018 Filed Jun 2, 2018 00:54 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | Exercise / conversionRestricted Stock Units · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001162194-18-000074 · wf-form4_152790080790416.xml · derivative · entry 4 Paya Carlos V · CIK 0001606244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of FLDM common stock upon vesting of the unit. F3 · derivative.exercise_date: On August 1, 2017, the Reporting Person was granted Restricted Stock Units, vesting fully on the earlier to occur of: (i) one day prior to the date of the next annual meeting of the stockholders of the Company; or (ii) August 1, 2018, subject to continued service as a director through the vesting date. F3 · derivative.expiration_date: On August 1, 2017, the Reporting Person was granted Restricted Stock Units, vesting fully on the earlier to occur of: (i) one day prior to the date of the next annual meeting of the stockholders of the Company; or (ii) August 1, 2018, subject to continued service as a director through the vesting date. Read SEC document |
| May 30, 2018 Filed Jun 2, 2018 00:54 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | Exercise / conversionCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001162194-18-000074 · wf-form4_152790080790416.xml · nonDerivative · entry 2 Paya Carlos V · CIK 0001606244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,734 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 30, 2018 Filed Jun 2, 2018 00:54 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | Exercise / conversionCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001162194-18-000074 · wf-form4_152790080790416.xml · nonDerivative · entry 1 Paya Carlos V · CIK 0001606244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,734 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 23, 2018 Filed Mar 27, 2018 00:57 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | Exercise / conversionRestricted Stock Units · Derivative | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001162194-18-000044 · wf-form4_152211223751732.xml · derivative · entry 2 Paya Carlos V · CIK 0001606244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 2,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of FLDM common stock upon vesting of the unit. F2 · derivative.exercise_date: On March 23, 2017, the Reporting Person was granted 10,000 Restricted Stock Units, of which 25% of the total number of shares underlying the Restricted Stock Units have vested and will continue to vest on each anniversary after the date of grant on the same day of the month as the date of grant until fully vested, subject to continued service as a director through each such date. F2 · derivative.expiration_date: On March 23, 2017, the Reporting Person was granted 10,000 Restricted Stock Units, of which 25% of the total number of shares underlying the Restricted Stock Units have vested and will continue to vest on each anniversary after the date of grant on the same day of the month as the date of grant until fully vested, subject to continued service as a director through each such date. Read SEC document |
| March 23, 2018 Filed Mar 27, 2018 00:57 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | Exercise / conversionCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001162194-18-000044 · wf-form4_152211223751732.xml · nonDerivative · entry 1 Paya Carlos V · CIK 0001606244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,734 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2018 Filed Feb 15, 2018 22:53 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | GrantCommon Stock | 5,952 | $0.00 | $0.00 |
DisclosureSEC source: 0001162194-18-000014 · wf-form4_151873521437770.xml · nonDerivative · entry 1 Paya Carlos V · CIK 0001606244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,234 F1 · shares: Each Restricted Stock Unit represents the contingent right to receive one share of FLDM common stock upon vesting of the unit. Subject to the Reporting Person's continued service with the Issuer through each applicable vesting date, twenty-five percent (25%) of the shares underlying the Restricted Stock Units shall vest quarterly on the last day of each quarter during 2018. Read SEC document |
| January 05, 2018 Filed Jan 8, 2018 20:21 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | SaleCommon Stock | 7,970 | $4.17 | $33,246.86 |
DisclosureSEC source: 0001209191-18-002810 · doc4.xml · nonDerivative · entry 2 Paya Carlos V · CIK 0001606244 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,590 F3 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan that was included in the Reporting Person's restricted stock unit agreements, dated January 4, 2016 and January 4, 2017, in order to satisfy a tax liability incurred upon the vesting of restricted stock units on January 4, 2018. F3 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan that was included in the Reporting Person's restricted stock unit agreements, dated January 4, 2016 and January 4, 2017, in order to satisfy a tax liability incurred upon the vesting of restricted stock units on January 4, 2018. Read SEC document |
| January 04, 2018 Filed Jan 8, 2018 20:21 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | GrantStock Option (right to buy) · Derivative | 216,500 | $0.00 Strike: $4.05 | $0.00 |
DisclosureSEC source: 0001209191-18-002810 · doc4.xml · derivative · entry 3 Paya Carlos V · CIK 0001606244 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,500 Underlying: Common Stock · 216,500 shares Expires 2028-01-04 F4 · derivative.exercise_date: One quarter of the shares underlying the option will vest on January 4, 2019, and the remainder of the shares underlying the option will vest at a rate of 1/24th per month thereafter, subject to the Reporting Person's continuous service through each such date. Read SEC document |
| January 04, 2018 Filed Jan 8, 2018 20:21 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | GrantCommon Stock | 46,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-002810 · doc4.xml · nonDerivative · entry 1 Paya Carlos V · CIK 0001606244 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,560 F1 · security: Each restricted stock unit represents a contingent right to receive one share of Immune Design Corp. common stock. F2 · shares: Restricted stock units shall vest in a series of three equal consecutive annual installments beginning on January 4, 2019, subject to the Reporting Person's continuous service through each such date. Read SEC document |
| December 31, 2017 Filed Jan 3, 2018 21:51 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | Exercise / conversionRestricted Stock Units · Derivative | 3,641 | $0.00 | $0.00 |
DisclosureSEC source: 0001162194-18-000005 · wf-form4_151501629519980.xml · derivative · entry 2 Paya Carlos V · CIK 0001606244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,641 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of FLDM common stock upon vesting of the unit. F2 · derivative.exercise_date: Fifty percent (50%) of the shares underlying the Restricted Stock Units vested on September 30, 2017, and the remaining fifty percent (50%) vested on December 31, 2017. F2 · derivative.expiration_date: Fifty percent (50%) of the shares underlying the Restricted Stock Units vested on September 30, 2017, and the remaining fifty percent (50%) vested on December 31, 2017. Read SEC document |
| December 31, 2017 Filed Jan 3, 2018 21:51 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | Exercise / conversionCommon Stock | 3,641 | $0.00 | $0.00 |
DisclosureSEC source: 0001162194-18-000005 · wf-form4_151501629519980.xml · nonDerivative · entry 1 Paya Carlos V · CIK 0001606244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,282 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 30, 2017 Filed Oct 3, 2017 00:55 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | Exercise / conversionRestricted Stock Units · Derivative | 3,641 | $0.00 | $0.00 |
DisclosureSEC source: 0001162194-17-000152 · wf-form4_150699210164382.xml · derivative · entry 2 Paya Carlos V · CIK 0001606244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,641 Underlying: Common Stock · 3,641 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of FLDM common stock upon vesting of the unit. F2 · derivative.exercise_date: Fifty percent (50%) of the shares underlying the Restricted Stock Units vested on September 30, 2017, and the remaining fifty percent (50%) will vest on December 31, 2017 subject to serving as a director through such date. F2 · derivative.expiration_date: Fifty percent (50%) of the shares underlying the Restricted Stock Units vested on September 30, 2017, and the remaining fifty percent (50%) will vest on December 31, 2017 subject to serving as a director through such date. Read SEC document |
| September 30, 2017 Filed Oct 3, 2017 00:55 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | Exercise / conversionCommon Stock | 3,641 | $0.00 | $0.00 |
DisclosureSEC source: 0001162194-17-000152 · wf-form4_150699210164382.xml · nonDerivative · entry 1 Paya Carlos V · CIK 0001606244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,641 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 13, 2017 Filed Sep 15, 2017 01:06 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | GrantStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $5.44 | $0.00 |
DisclosureSEC source: 0001162194-17-000131 · wf-form4_150543759473189.xml · derivative · entry 2 Paya Carlos V · CIK 0001606244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires 2027-08-01 F3 · derivative.exercise_date: 1/12th of the total number of shares subject to the Option will vest each month after the Vesting Commencement Date, on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), such that the Option will be fully vested one year following the Vesting Commencement Date, subject to recipient continuing to serve as a director of the Company through each such vesting date. "Vesting Commencement Date" shall mean August 1, 2017. Read SEC document |
| September 13, 2017 Filed Sep 15, 2017 01:06 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | GrantRestricted Stock Units · Derivative | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001162194-17-000131 · wf-form4_150543759473189.xml · derivative · entry 1 Paya Carlos V · CIK 0001606244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of FLDM common stock upon vesting of the unit. F2 · derivative.exercise_date: All shares underlying the Restricted Stock Units will fully vest on the earlier to occur of (i) one day prior to the date of the next annual meeting of the stockholders of the Company or (ii) August 1, 2018, in each case subject to recipient's continued service as a director through the applicable vest date. F2 · derivative.expiration_date: All shares underlying the Restricted Stock Units will fully vest on the earlier to occur of (i) one day prior to the date of the next annual meeting of the stockholders of the Company or (ii) August 1, 2018, in each case subject to recipient's continued service as a director through the applicable vest date. Read SEC document |
| August 08, 2017 Filed Aug 10, 2017 20:45 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | GrantRestricted Stock Units · Derivative | 7,282 | $0.00 | $0.00 |
DisclosureSEC source: 0001162194-17-000111 · wf-form4_150239792599532.xml · derivative · entry 1 Paya Carlos V · CIK 0001606244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,282 Underlying: Common Stock · 7,282 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of FLDM common stock upon vesting of the unit. F2 · derivative.exercise_date: Fifty percent (50%) of the shares underlying the Restricted Stock Units will vest on September 30, 2017, and the remaining fifty percent (50%) will vest on December 31, 2017, in each case subject to serving as a director through such date. F2 · derivative.expiration_date: Fifty percent (50%) of the shares underlying the Restricted Stock Units will vest on September 30, 2017, and the remaining fifty percent (50%) will vest on December 31, 2017, in each case subject to serving as a director through such date. Read SEC document |
| August 01, 2017 Filed Aug 3, 2017 00:32 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | GrantCommon Stock · Derivative | 5,000 | $0.00 Strike: $3.43 | $0.00 |
DisclosureSEC source: 0001162194-17-000082 · wf-form4_150172032970669.xml · derivative · entry 2 Paya Carlos V · CIK 0001606244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2027-08-01 F3 · derivative.exercise_date: 1/12th of the shares subject to the Option will vest monthly, subject to continued service as a director, such that the Option will be fully vested on August 1, 2018. Read SEC document |
| August 01, 2017 Filed Aug 3, 2017 00:32 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | GrantRestricted Stock Units · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001162194-17-000082 · wf-form4_150172032970669.xml · derivative · entry 1 Paya Carlos V · CIK 0001606244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of FLDM common stock upon vesting of the unit. F2 · derivative.exercise_date: All shares underlying the Restricted Stock Units will fully vest on the earlier to occur of one day prior to the date of the next annual meeting of the stockholders of the Company or August 1, 2018, subject to continued service as a director through the vesting date. F2 · derivative.expiration_date: All shares underlying the Restricted Stock Units will fully vest on the earlier to occur of one day prior to the date of the next annual meeting of the stockholders of the Company or August 1, 2018, subject to continued service as a director through the vesting date. Read SEC document |
| March 23, 2017 Filed Mar 27, 2017 17:25 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | GrantEmployee Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $5.52 | $0.00 |
DisclosureSEC source: 0001162194-17-000031 · wf-form4_149063551466888.xml · derivative · entry 2 Paya Carlos V · CIK 0001606244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-03-23 F3 · derivative.exercise_date: 25% of the shares subject to the Option will vest each anniversary after the date of grant on the same day of the month as the date of grant, subject to continued service as a director. Read SEC document |
| March 23, 2017 Filed Mar 27, 2017 17:25 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | GrantRestricted Stock Units · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001162194-17-000031 · wf-form4_149063551466888.xml · derivative · entry 1 Paya Carlos V · CIK 0001606244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of FLDM common stock upon vesting of the unit. F2 · derivative.exercise_date: 25% of the shares underlying the Restricted Stock Units will vest each anniversary after the date of grant on the same day of the month as the date of grant, subject to continued service as a director. F2 · derivative.expiration_date: 25% of the shares underlying the Restricted Stock Units will vest each anniversary after the date of grant on the same day of the month as the date of grant, subject to continued service as a director. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 21:32 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | GrantStock Option (right to buy) · Derivative | 175,000 | $0.00 Strike: $5.60 | $0.00 |
DisclosureSEC source: 0001209191-17-002805 · doc4.xml · derivative · entry 3 Paya Carlos V · CIK 0001606244 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2027-01-04 F5 · derivative.exercise_date: One quarter of the shares underlying the option will vest on January 4, 2018, and the remainder of the shares underlying the option will vest at a rate of 1/36th per month thereafter, subject to the Reporting Person's continuous service through each such date. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 21:32 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | SaleCommon Stock | 3,940 | $5.35 | $21,079.00 |
DisclosureSEC source: 0001209191-17-002805 · doc4.xml · nonDerivative · entry 2 Paya Carlos V · CIK 0001606244 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,060 F3 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan that was included in the Reporting Person's restricted stock unit agreement, dated January 4, 2016, in order to satisfy a tax liability incurred upon the vesting of restricted stock units on January 4, 2017. F3 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan that was included in the Reporting Person's restricted stock unit agreement, dated January 4, 2016, in order to satisfy a tax liability incurred upon the vesting of restricted stock units on January 4, 2017. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.25 to $5.42 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 21:32 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | GrantCommon Stock | 36,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-002805 · doc4.xml · nonDerivative · entry 1 Paya Carlos V · CIK 0001606244 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,000 F1 · security: Each restricted stock unit represents a contingent right to receive one share of Immune Design Corp. common stock. F2 · shares: One quarter of the total restricted stock units vest annually beginning January 4, 2018, subject to the Reporting Person's continuous service through each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.